GMAB Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

29.410

Open

29.070

VWAP

29.10

Vol

1.13M

Mkt Cap

17.20B

Low

28.830

Amount

32.75M

EV/EBITDA(TTM)

15.32

Total Shares

613.94M

21.27B

EV/OCF(TTM)

23.58

P/S(TTM)

4.50

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Events Timeline

(ET)

2026-07-06

14:00:00

Genmab Receives Approval for TEPKINLY in Combination Therapy for Relapsed Follicular Lymphoma

2026-06-29 (ET)

2026-06-29

16:30:00

Genmab EPCORE DLBCL-4 Trial Results Significantly Improve Survival Rates

2026-06-29

16:30:00

Genmab Reports Significant Results from EPCORE DLBCL-4 Trial

2026-06-29

16:30:00

AbbVie Reports Positive Results from EPCORE DLBCL-4 Trial

2026-06-14 (ET)

2026-06-14

17:30:00

Genmab Reports New Epcoritamab Data, 93% ORR in Elderly DLBCL Patients

News

9.0

09:04 AMNASDAQ.COM

PinnedGenmab's TEPKINLY Approved by EU for Follicular Lymphoma

8.5

07-06Newsfilter

PinnedTEPKINLY® Approved in Europe for Relapsed Follicular Lymphoma Treatment

9.0

17:11 PMseekingalpha

European Commission Approves Tepkinly Label Expansion for Blood Cancer Therapy

8.5

09:04 AMYahoo Finance

Genmab's Tepkinly Approved by European Commission

9.0

06-29seekingalpha

AbbVie's Epkinly Shows Significant Survival Benefits in Lymphoma Patients

9.0

06-29Yahoo Finance

Genmab Phase 3 Study Success

7 Analyst Rating

Wall Street analysts forecast GMAB stock price to rise

5 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

26.00

Averages

38.50

High

48.00

Current: 0.000

Low

26.00

Averages

38.50

High

48.00

H.C. Wainwright

Raghuram Selvaraju

Buy

maintain

$38 -> $40

AI Analysis

2026-07-02

New

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$38 -> $40

AI Analysis

2026-07-02

New

maintain

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Genmab to $40 from $38 and keeps a Buy rating on the shares after the company announced that the EPCORE DLBCL-4 trial met its primary objective. The firm increased the probability of approval for Epkinly in both the first- and second-line setting to 70% and 95%, respectively.

Truist

Gregory Renza

Buy

Strong Buy

downgrade

$48 -> $40

2026-05-27

Reason

Truist

Gregory Renza

Price Target

$48 -> $40

2026-05-27

downgrade

Buy

Strong Buy

Reason

Truist analyst Gregory Renza assumed coverage of Genmab with a Buy rating and a price target of $40, down from $48. The firm is positive on the company's transition toward a commercially driven platform, supported by three lead assets with up to seven key readouts in 2026, the analyst tells investors in a research note. Epkinly's DLBCL-2/-4 outcomes are pivotal for franchise expansion, with Rina-S and petosemtamab carrying potential for best-/first-in-class positioning in ovarian cancer and HNSCC, respectively, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GMAB

Unlock Now

Valuation Metrics

The current forward P/E ratio for Genmab A/S (GMAB.O) is 16.92, compared to its 5-year average forward P/E of 31.63. For a more detailed relative valuation and DCF analysis to assess Genmab A/S's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

31.63

Current PE

16.92

Overvalued PE

52.66

Undervalued PE

10.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

22.55

Current EV/EBITDA

2.59

Overvalued EV/EBITDA

47.45

Undervalued EV/EBITDA

-2.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.15

Current PS

0.54

Overvalued PS

13.47

Undervalued PS

2.83

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

growth stock

Intellectia · 35 candidates

Market Cap: >= 5.00BSector: Consumer Cyclicals, Consumer Non-Cyclicals, Financial Technology (Fintech) & Infrastructure, Healthcare, Healthcare Services & Equipment, Technology, Technology Equipment, Telecommunications ServicesRegion: USMarket Cap Category: large, midAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 15Eps 5yr Cagr: >= 15List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Fabrinet

18.06B

CLS

Celestica Inc

35.38B

CELH

Celsius Holdings Inc

13.04B

KLAC

KLA Corp

189.14B

APH

Amphenol Corp

166.75B

NVMI

Nova Ltd

13.64B

what stocks would you recommend?

Intellectia · 28 candidates

Market Cap: >= 10.00BPrice: $10.00 - $250.00Quarter Revenue Yoy Growth: >= 10.0%Analyst Consensus: Strong Buy, Moderate BuyNet Margin: >= 8.00Rsi Category: moderateTarget Price Upside Potential: AbovePrice, MoreAbovePriceMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Annual Revenue Yoy Growth: >= 10.0%Free Cash Flow Ttm: >= 0Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

NVDA

NVIDIA Corp

4.49T

AMD

Advanced Micro Devices Inc

339.29B

NEE

Nextera Energy Inc

185.37B

ANET

Arista Networks Inc

171.33B

APH

Amphenol Corp

157.08B

ARM

Arm Holdings PLC

129.42B

from those 83, pick the best 8

Intellectia · 84 candidates

Market Cap: >= 10.00BRegion: USRevenue 5yr Cagr: >= 10Eps 5yr Cagr: >= 10List Exchange: XNYS, XNASReturn On Equity: >= 15.0%

Ticker

Name

Market Cap$

FUTU

Futu Holdings Ltd

20.83B

NVDA

NVIDIA Corp

4.21T

APO

Apollo Global Management Inc

73.03B

APP

Applovin Corp

130.97B

IBKR

Interactive Brokers Group Inc

119.46B

GMAB

Genmab A/S

19.56B

what is a good buy

Intellectia · 33 candidates

Market Cap: >= 20.00BRegion: USAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 10Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%

Ticker

Name

Market Cap$

FUTU

Futu Holdings Ltd

22.22B

PDD

PDD Holdings Inc

146.24B

COIN

Coinbase Global Inc

51.23B

APO

Apollo Global Management Inc

71.36B

RCL

Royal Caribbean Cruises Ltd

89.58B

CCL

Carnival Corp

45.93B

high returns

Intellectia · 56 candidates

Market Cap: >= 5.00BRevenue 5yr Cagr: >= 15List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 18.0%Annual Eps Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

CLS

Celestica Inc

32.32B

APH

Amphenol Corp

176.36B

PRIM

Primoris Services Corp

8.01B

ASML

ASML Holding NV

551.27B

KLAC

KLA Corp

187.62B

HOOD

Robinhood Markets Inc

89.45B

Growth stocks to invest in

Intellectia · 24 candidates

Market Cap: >= 5.00BRegion: USQuarter Revenue Yoy Growth: >= 20.0%Market Cap Category: large, midRevenue 5yr Cagr: >= 15Eps 5yr Cagr: >= 15List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

CELH

Celsius Holdings Inc

13.94B

FUTU

Futu Holdings Ltd

22.82B

DOCS

Doximity Inc

7.33B

ATAT

Atour Lifestyle Holdings Ltd

5.01B

AXON

Axon Enterprise Inc

45.20B

GMAB

Genmab A/S

20.27B

what are the top 5 stocks for 2026 to buy

Intellectia · 10 candidates

Market Cap: >= 10.00BRevenue 5yr Cagr: >= 15Eps 5yr Cagr: >= 15Pe Ttm: <= 25Return On Equity: >= 15.0%

Ticker

Name

Market Cap$

FUTU

Futu Holdings Ltd

23.11B

KSPI

Kaspi.kz AO

14.51B

GMAB

Genmab A/S

20.30B

MPWR

Monolithic Power Systems Inc

51.50B

RNR

Renaissancere Holdings Ltd

12.65B

LULU

Lululemon Athletica Inc

22.27B

what are the top 10 growth stocks?

Intellectia · 14 candidates

Quarter Revenue Yoy Growth: >= 25.0%Quarter Eps Yoy Growth: >= 20.0%Revenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 15Free Cash Flow 5yr Cagr: >= 10

Ticker

Name

Market Cap$

FUTU

Futu Holdings Ltd

23.11B

NVDA

NVIDIA Corp

4.45T

PLMR

Palomar Holdings Inc

3.45B

ATAT

Atour Lifestyle Holdings Ltd

5.22B

ISSC

Innovative Solutions and Support Inc

392.68M

GMAB

Genmab A/S

20.30B

what one stock I can buy now all in

Intellectia · 8 candidates

Market Cap: >= 10.00BWeekly Average Turnover: >= 1,000,000Pe Ttm: 12 - 20Return On Equity: >= 20.0%Annual Revenue Yoy Growth: >= 15.0%

Ticker

Name

Market Cap$

NVO

Novo Nordisk A/S

263.42B

NEM

Newmont Corporation

129.76B

Anglogold Ashanti PLC

51.18B

KGC

Kinross Gold Corp

43.05B

FUTU

Futu Holdings Ltd

23.11B

GMAB

Genmab A/S

20.30B

Pick 4 stocks that project large growth

Intellectia · 26 candidates

Revenue 5yr Cagr: >= 15Eps 5yr Cagr: >= 15Weekly Average Turnover: >= 1,000,000Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%Quarter Eps Qoq Growth: >= 10.0%

Ticker

Name

Market Cap$

NVDA

NVIDIA Corp

4.45T

TSM

Taiwan Semiconductor Manufacturing Co Ltd

1.69T

AVGO

Broadcom Inc

1.56T

IBKR

Interactive Brokers Group Inc

128.56B

MPWR

Monolithic Power Systems Inc

51.50B

Tradeweb Markets Inc

24.53B

Whales Holding GMAB

Paradigm Biocapital Advisors LP

Evli Fund Management Company Ltd.

Union Bancaire Privée, UBP SA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Genmab A/S (GMAB) stock price today?

The current price of GMAB is 29.05 USD — it has increased 3.71

What is Genmab A/S (GMAB)'s business?

What is the price predicton of GMAB Stock?

Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is38.50 USD with a low forecast of 26.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.